AIMS: To document the haemodynamic, neurohormonal, and renal responses to Urocortin 2 (UCN2) infused in human heart failure (HF). METHODS AND RESULTS:Eight male patients with HF [left ventricular ejection fraction (LVEF) <; 40%, NYHA class II-III] received placebo and 25 [low dose (LD)] and 100 microg [high dose (HD)] of UCN2 intravenously over 1 h in a single-blind, placebo-controlled, dose-escalation design. UCN2 increased cardiac output (CO) (mean peak increments +/- SEM; placebo 0.3 +/- 0.1; LD 1.0 +/- 0.3; HD 2.0 +/- 0.2 L/min; P < 0.001) and LVEF (0.0 +/- 1.5; LD 5.9 +/- 2.1; HD 14.1 +/- 2.7%; P = 0.001) and decreased mean arterial pressure (placebo 6.7 +/- 1.3; LD 11.4 +/- 1.7; HD 19.4 +/- 3.3 mmHg; P = 0.001), systemic vascular resistance (SVR) (placebo 104 +/- 37; LD 281 +/- 64; HD 476 +/- 79 dynes s/cm(5); P < 0.003), and cardiac work (CW) (placebo 48 +/- 12; LD 66 +/- 22; HD 94 +/- 13 mmHg/L/min; P < 0.001). No significant effect on vasoconstrictor/volume-retaining neurohormones was noted. UCN2 decreased urinary volume (P = 0.035) but not creatinine excretion (P = 0.962). CONCLUSION: Intravenous UCN2 in HF induced increases in CO and LVEF with falls in SVR and CW. No hormone response occurred. The role of UCN2 in circulatory regulation and its potential therapeutic application in heart disease warrant further investigation.
RCT Entities:
AIMS: To document the haemodynamic, neurohormonal, and renal responses to Urocortin 2 (UCN2) infused in humanheart failure (HF). METHODS AND RESULTS: Eight male patients with HF [left ventricular ejection fraction (LVEF) < 40%, NYHA class II-III] received placebo and 25 [low dose (LD)] and 100 microg [high dose (HD)] of UCN2 intravenously over 1 h in a single-blind, placebo-controlled, dose-escalation design. UCN2 increased cardiac output (CO) (mean peak increments +/- SEM; placebo 0.3 +/- 0.1; LD 1.0 +/- 0.3; HD 2.0 +/- 0.2 L/min; P < 0.001) and LVEF (0.0 +/- 1.5; LD 5.9 +/- 2.1; HD 14.1 +/- 2.7%; P = 0.001) and decreased mean arterial pressure (placebo 6.7 +/- 1.3; LD 11.4 +/- 1.7; HD 19.4 +/- 3.3 mmHg; P = 0.001), systemic vascular resistance (SVR) (placebo 104 +/- 37; LD 281 +/- 64; HD 476 +/- 79 dynes s/cm(5); P < 0.003), and cardiac work (CW) (placebo 48 +/- 12; LD 66 +/- 22; HD 94 +/- 13 mmHg/L/min; P < 0.001). No significant effect on vasoconstrictor/volume-retaining neurohormones was noted. UCN2 decreased urinary volume (P = 0.035) but not creatinine excretion (P = 0.962). CONCLUSION: Intravenous UCN2 in HF induced increases in CO and LVEF with falls in SVR and CW. No hormone response occurred. The role of UCN2 in circulatory regulation and its potential therapeutic application in heart disease warrant further investigation.
Authors: Ji Li; Dake Qi; Haiying Cheng; Xiaoyue Hu; Edward J Miller; Xiaohong Wu; Kerry S Russell; Nicole Mikush; Jiasheng Zhang; Lei Xiao; Robert S Sherwin; Lawrence H Young Journal: Proc Natl Acad Sci U S A Date: 2013-09-16 Impact factor: 11.205
Authors: K Patel; M T Rademaker; C M J Kirkpatrick; C J Charles; S Fisher; T G Yandle; A M Richards Journal: Br J Pharmacol Date: 2012-07 Impact factor: 8.739
Authors: Catherine A Makarewich; Constantine D Troupes; Sarah M Schumacher; Polina Gross; Walter J Koch; David L Crandall; Steven R Houser Journal: J Mol Cell Cardiol Date: 2015-07-29 Impact factor: 5.000
Authors: Mei Hua Gao; N Chin Lai; Atsushi Miyanohara; Jan M Schilling; Jorge Suarez; Tong Tang; Tracy Guo; Ruoying Tang; Jay Parikh; Dimosthenis Giamouridis; Wolfgang H Dillmann; Hemal H Patel; David M Roth; Nancy D Dalton; H Kirk Hammond Journal: Hum Gene Ther Date: 2013-09 Impact factor: 5.695